Modelled CKD Benefits of Broad Sodium-Glucose Cotransporter-2 Inhibitor Eligibility in the UK Authors: Navdeep Tangri, Stacey Priest, Anthony Zara, Bo Ren Long, Naveen Rao, Clélia-Elsa Froguel, Fiona Adshead, Steven Chadban Published: 2026 ABSTRACT IntroductionChronic kidney disease (CKD) affects >10% of the UK population and is expected to increase. Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) are effective at slowing CKD progression; however, they are underprescribed because of barriers, including the need for urine albumin-creatinine ratio (UACR) testing and lack of guideline alignment. This study sought to quantify the clinical, economic, and environmental trade-offs of broad and restrictive SGLT-2i access in the UK.MethodsFive scenarios exploring a range of SGLT-2i eligibility criteria for patients with CKD were modelled over 10 years, beginning from 2025, using the validated IMPACT CKD individual-level microsimulation model. SGLT-2i treatment was modelled to improve estimated glomerular filtration rate (eGFR) decline and reduce cardiovascular (CV) events and acute kidney injury. A 3.5%/yr discount was applied to economic outcomes.ResultsA maximally inclusive SGLT-2i scenario was compared with each of the less inclusive SGLT-2i eligibility criteria scenarios. Increasingly restrictive scenarios were projected to increase dialysis and all-cause mortality by 4.0% to 17.2% and 1.3% to 4.3%, respectively. Resulting from higher mortality, CKD prevalence was projected to decrease by 0.5% to 1.4%. Non–kidney replacement therapy (KRT) CKD costs and KRT costs were projected to increase by 0.7% to 2.1% and 2.4% to 10.6%, respectively, with increasingly restrictive scenarios. Total costs were projected to decrease by 15.2% to 33.9% because fewer patients are treated. Because of shifts to later stages, KRT-related environmental burden was projected to increase by 3.1% to 14.9%.ConclusionBroad SGLT-2i eligibility criteria would likely reduce the holistic burden of CKD for patients, the National Health Service (NHS), and the environment. CKD imposes growing clinical, economic, and environmental burdens in the UK; affecting approximately 7.2 million individuals and driving substantial long-term KRT (dialysis and transplant) needs and elevated mortality risk.1,2 Increasing need for KRT contributes to greater environmental strain because dialysis, the dominant form of KRT, requires high consumption of energy, water, and single-use plastics. In high-income countries, KRT also drives health care costs, with an estimated cost ≤ 3% of annual health care budget in a given country and an estimated mortality rate of 15% to 20% within the first 12 months of patients starting dialysis.2,3 The burden of CKD is expected to increase driven by an aging population, as well as the increase in other risk factors such as diabetes, hypertension, CV diseases, as well as health and economic inequalities.1 Previously, the IMPACT CKD microsimulation model was used to project the burden of CKD across clinical, health care resource use, economic, societal, patient, and environmental outcomes in the UK.4 Overall CKD prevalence was projected to increase by 7.7% over a 10-year period and patients requiring KRT was projected to increase by 66.2%. The economic and environmental burden were projected to increase, driven by the increases in CKD prevalence. Therefore, there is a clear need for implementation of strategies to mitigate the holistic burden of CKD in the UK through reducing barriers to effective CKD care, including improving access to and uptake of effective CKD therapies. SGLT-2is are a first-line effective therapeutic option that have been shown to delay CKD progression and reduce the occurrence of CV events.5 Recent literature shows that SGLT-2is provide consistent kidney and CV benefits in patients with CKD, regardless of diabetes status; however, the magnitude of benefits likely varies according to an individual’s risk of kidney-related and CV complications.6 Despite their effectiveness, SGLT-2is are underprescribed in the UK due in part to a lack of alignment between the various guidelines, including Kidney Disease: Improving Global Outcomes (KDIGO),7 the UK Kidney Association,8 and the UK National Institute for Health and Care Excellence.9,10 Typically, guidelines recommend SGLT-2i prescription to patients with type 2 diabetes (T2D) or CKD with varying thresholds of eligibility based on eGFR and UACR. In addition, recent guidelines informed by a systematic review and meta-analysis recommend SGLT-2is to all adults with CKD, irrespective of diabetes status or baseline CKD risk.11,12 Additional barriers to SGLT-2i eligibility exist and may further limit access to the effective CKD therapy.13 A recent large population-based study showed that out of 516,491 patients with CKD, only 138,183 (27%) were eligible for SGLT-2i according to ≥1 criterion across 3 UK guidelines, and the American Diabetes Association–KDIGO 2022 guidelines.8, 9, 10,14 Factors associated with lower likelihood of SGLT-2i prescription, which likely represent barriers to access, include lower socioeconomic status, female sex, black ethnicity, and increasing age.13 Across all guidelines, UACR criteria alone can result in the exclusion of up to 65% of patients because of either an absence of albuminuria or albuminuria at a level below guideline threshold, and up to 34% of patients because of a lack of UACR measurement entirely.13 Therefore, though effective therapies such as SGLT-2is exist, they are not routinely used because of the abovementioned barriers, aggravating the long-term burden of CKD. Knowledge on the population-level long-term impacts of broader SGLT-2i use is needed so that governing bodies and policymakers can develop additional strategies to improve access-to-care. We used a validated individual-level microsimulation model to evaluate the clinical, economic, and environmental trade-offs of various SGLT-2i eligibility broadening scenarios to provide insights into the potential long-term impacts among patients with CKD in the UK. Methods Model Simulation Overview The IMPACT CKD model is an extensively validated individual-level microsimulation model designed to simulate CKD development and progression, and has been previously described in detail.4,15,16 This manuscript reports on an analysis using the IMPACT CKD model conducted to understand the comprehensive impact of SGLT-2is on CKD burdens over time in the UK. A 10-year time horizon was used (base year: 2025; 10 simulated years: 2026–2035). Country-specific births and immigration were considered in the model to account for population growth, with individuals allowed to develop CKD over the time horizon. Population-level characteristics, CKD-related CV complications (myocardial infarction [MI], stroke, heart failure hospitalization), comorbidities, and mortality (based on the following hierarchy: KRT-related mortality, CV-related mortality, mortality in the CKD population by stage, and mortality in the general population) were captured to model the pathway of the disease. In each cycle, patients could be assigned ≥1 CV events, comorbidities, and/or death based on individual event probabilities. Rates and effect of current treatment use were parameterized consistently with previous IMPACT CKD analyses.4,15,16 Furthermore, the model has been previously calibrated and validated using historical UK-specific epidemiological and clinical data.4 Primary Scenarios Various broad and restrictive SGLT-2i threshold scenarios were assessed and compared. The following 5 primary scenario analyses were simulated, progressing from the broadest to the most restrictive:1.Scenario 1 – Broad CKD accessoAll patients with CKD are eligible for SGLT-2i therapy, regardless of diabetes status, eGFR, or albuminuria level, reflective of recent guidelines.11oRepresents a maximally inclusive policy.2.Scenario 2 – KDIGO 2024-Guideline accessoEligibility mirrors the 2024 KDIGO recommendations,7 including the following:oAll patients with T2D and eGFR ≥ 20 ml/min per 1.73 m2oAll patients with history of heart failureoAll patients with eGFR ≥20 and UACR ≥200 mg/goAll patients with eGFR 20–45 and UACR <200 mg/goReflects a risk-based, evidence-informed policy.3.Scenario 3 – Restricted Non-T2D Access (UACR < 200 mg/g)oSGLT-2i access is granted to patients with T2D and selected patients without T2D, but excludes patients without T2D with UACR < 200 mg/g.oSimulates the current UK National Institute for Health and Care Excellence–recommended approach.104.Scenario 4 – High albuminuria-only access (UACR ≥ 200 mg/g)oAccess is restricted solely to patients with CKD with UACR ≥ 200 mg/g, regardless of diabetes status.oRepresents the most restrictive, albuminuria-threshold–based policy.5.Scenario 5 – Current usageoSGLT-2i access reflects current usage by eGFR. 1.Scenario 1 – Broad CKD accessoAll patients with CKD are eligible for SGLT-2i therapy, regardless of diabetes status, eGFR, or albuminuria level, reflective of recent guidelines.11oRepresents a maximally inclusive policy. Scenario 1 – Broad CKD accessoAll patients with CKD are eligible for SGLT-2i therapy, regardless of diabetes status, eGFR, or albuminuria level, reflective of recent guidelines.11oRepresents a maximally inclusive policy. oAll patients with CKD are eligible for SGLT-2i therapy, regardless of diabetes status, eGFR, or albuminuria level, reflective of recent guidelines.11 All patients with CKD are eligible for SGLT-2i therapy, regardless of diabetes status, eGFR, or albuminuria level, reflective of recent guidelines.11 oRepresents a maximally inclusive policy. Represents a maximally inclusive policy. 2.Scenario 2 – KDIGO 2024-Guideline accessoEligibility mirrors the 2024 KDIGO recommendations,7 including the following:oAll patients with T2D and eGFR ≥ 20 ml/min per 1.73 m2oAll patients with history of heart failureoAll patients with eGFR ≥20 and UACR ≥200 mg/goAll patients with eGFR 20–45 and UACR <200 mg/goReflects a risk-based, evidence-informed policy. Scenario 2 – KDIGO 2024-Guideline accessoEligibility mirrors the 2024 KDIGO recommendations,7 including the following:oAll patients with T2D and eGFR ≥ 20 ml/min per 1.73 m2oAll patients with history of heart failureoAll patients with eGFR ≥20 and UACR ≥200 mg/goAll patients with eGFR 20–45 and UACR <200 mg/goReflects a risk-based, evidence-informed policy. oEligibility mirrors the 2024 KDIGO recommendations,7 including the following: Eligibility mirrors the 2024 KDIGO recommendations,7 including the following: oAll patients with T2D and eGFR ≥ 20 ml/min per 1.73 m2 All patients with T2D and eGFR ≥ 20 ml/min per 1.73 m2 oAll patients with history of heart failure All patients with history of heart failure oAll patients with eGFR ≥20 and UACR ≥200 mg/g All patients with eGFR ≥20 and UACR ≥200 mg/g oAll patients with eGFR 20–45 and UACR <200 mg/g All patients with eGFR 20–45 and UACR <200 mg/g oReflects a risk-based, evidence-informed policy. Reflects a risk-based, evidence-informed policy. 3.Scenario 3 – Restricted Non-T2D Access (UACR < 200 mg/g)oSGLT-2i access is granted to patients with T2D and selected patients without T2D, but excludes patients without T2D with UACR < 200 mg/g.oSimulates the current UK National Institute for Health and Care Excellence–recommended approach.10 Scenario 3 – Restricted Non-T2D Access (UACR < 200 mg/g)oSGLT-2i access is granted to patients with T2D and selected patients without T2D, but excludes patients without T2D with UACR < 200 mg/g.oSimulates the current UK National Institute for Health and Care Excellence–recommended approach.10 oSGLT-2i access is granted to patients with T2D and selected patients without T2D, but excludes patients without T2D with UACR < 200 mg/g. SGLT-2i access is granted to patients with T2D and selected patients without T2D, but excludes patients without T2D with UACR < 200 mg/g. oSimulates the current UK National Institute for Health and Care Excellence–recommended approach.10 Simulates the current UK National Institute for Health and Care Excellence–recommended approach.10 4.Scenario 4 – High albuminuria-only access (UACR ≥ 200 mg/g)oAccess is restricted solely to patients with CKD with UACR ≥ 200 mg/g, regardless of diabetes status.oRepresents the most restrictive, albuminuria-threshold–based policy. Scenario 4 – High albuminuria-only access (UACR ≥ 200 mg/g)oAccess is restricted solely to patients with CKD with UACR ≥ 200 mg/g, regardless of diabetes status.oRepresents the most restrictive, albuminuria-threshold–based policy. oAccess is restricted solely to patients with CKD with UACR ≥ 200 mg/g, regardless of diabetes status. Access is restricted solely to patients with CKD with UACR ≥ 200 mg/g, regardless of diabetes status. oRepresents the most restrictive, albuminuria-threshold–based policy. Represents the most restrictive, albuminuria-threshold–based policy. 5.Scenario 5 – Current usageoSGLT-2i access reflects current usage by eGFR. Scenario 5 – Current usageoSGLT-2i access reflects current usage by eGFR. oSGLT-2i access reflects current usage by eGFR. SGLT-2i access reflects current usage by eGFR. SGLT-2i Treatment Inputs For each scenario (except for scenario 5, where no increased SGLT-2i uptake was modelled), 75% uptake among patients eligible for SGLT-2is was assumed to reflect real-world constraints in drug prescription and adherence. Additional sensitivity analyses were conducted for each scenario, including exploring 60% and 90% SGLT-2i uptake to assess the robustness of the projections. Current rate of SGLT-2i use was informed by various literature sources and expert opinion. Current and target use of SGLT-2i in each scenario can be found in Table 1. SGLT-2i use was modelled to improve eGFR decline, reduce occurrence of CV events (MI, stroke, and heart failure hospitalization), reduce acute kidney injury occurrence, and offer a 1-time improvement in UACR. Treatment effects were informed by the literature, and details can be found in Supplementary Table S1. The annual cost of SGLT-2i in the UK is £477.30 based on the UK National Institute for Health and Care Excellence’s technology appraisal guidance on dapagliflozin for the treatment of CKD.10 Cost discounting of 3.5% was applied annually at the aggregate level over the course of the model time horizon.18Table 1SGLT-2i treatment rates used in each scenario for patients with diagnosed CKDScenario (treated population with CKD)Patient populationStatus of useeGFR (ml/min per 1.73 m2)90+60–8945–5930–4420–29< 20All patients with CKDDiabetesCurrent use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%No diabetesCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%KDIGO guideline recommendationDiabetes + eGFR ≥ 20 ml/min per 1.73 m2Current use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%6.4%History of HFCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%eGFR ≥ 20 ml/min per 1.73 m2 + UACR ≥ 200 mg/gCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%6.4%eGFR ≥ 20-45 ml/min per 1.73 m2 + UACR < 200 mg/gCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use10.0%10.0%10.0%75.0%75.0%6.4%All T2D, restriction in non-T2D with UACR < 200 mg/gDiabetesCurrent use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%No Diabetes + UACR ≥ 200 mg/gCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%Restriction in all CKD with UACR < 200 mg/gDiabetes + UACR ≥ 200 mg/gCurrent use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%No diabetes + UACR ≥ 200 mg/gCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%Current usageDiabetesCurrent use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use18.2%18.4%15.5%15.5%6.6%6.4%No diabetesCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use10.0%10.0%10.0%10.0%6.6%6.4%CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; KDIGO, Kidney Disease: Improving Global Outcomes; SGLT-2i, sodium-glucose cotransporter 2 inhibitor; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio.aSGLT-2i current use in patients with CKD and diabetes was informed by SGLT-2i usage reported through claims data.17bClinical expert opinion. Table 1SGLT-2i treatment rates used in each scenario for patients with diagnosed CKDScenario (treated population with CKD)Patient populationStatus of useeGFR (ml/min per 1.73 m2)90+60–8945–5930–4420–29< 20All patients with CKDDiabetesCurrent use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%No diabetesCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%KDIGO guideline recommendationDiabetes + eGFR ≥ 20 ml/min per 1.73 m2Current use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%6.4%History of HFCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%eGFR ≥ 20 ml/min per 1.73 m2 + UACR ≥ 200 mg/gCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%6.4%eGFR ≥ 20-45 ml/min per 1.73 m2 + UACR < 200 mg/gCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use10.0%10.0%10.0%75.0%75.0%6.4%All T2D, restriction in non-T2D with UACR < 200 mg/gDiabetesCurrent use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%No Diabetes + UACR ≥ 200 mg/gCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%Restriction in all CKD with UACR < 200 mg/gDiabetes + UACR ≥ 200 mg/gCurrent use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%No diabetes + UACR ≥ 200 mg/gCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use75.0%75.0%75.0%75.0%75.0%75.0%Current usageDiabetesCurrent use17,a18.2%18.4%15.5%15.5%6.6%6.4%Target use18.2%18.4%15.5%15.5%6.6%6.4%No diabetesCurrent useb10.0%10.0%10.0%10.0%6.6%6.4%Target use10.0%10.0%10.0%10.0%6.6%6.4%CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; KDIGO, Kidney Disease: Improving Global Outcomes; SGLT-2i, sodium-glucose cotransporter 2 inhibitor; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio.aSGLT-2i current use in patients with CKD and diabetes was informed by SGLT-2i usage reported through claims data.17bClinical expert opinion. SGLT-2i treatment rates used in each scenario for patients with diagnosed CKD CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HF, heart failure; KDIGO, Kidney Disease: Improving Global Outcomes; SGLT-2i, sodium-glucose cotransporter 2 inhibitor; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio. SGLT-2i current use in patients with CKD and diabetes was informed by SGLT-2i usage reported through claims data.17 Clinical expert opinion. Analysis Assumptions There were several analysis assumptions, including that 100% of patients with CKD were diagnosed and eligible for risk stratification. In addition, background therapies were assumed for patients with CKD, such as renin-angiotensin-aldosterone system inhibitors, mineralocorticoid receptor antagonists, glucagon-like peptide 1 receptor agonists, lifestyle, and statins. All background therapies were not increased beyond their current background use to isolate the incremental impact of SGLT-2i use. Patients outside scenario-defined eligibility were not assigned SGLT-2i treatment. Treatment guidelines for SGLT-2i initiation were assumed to be constant over the 10-year time horizon. Results In the results, we compared the cumulative 10-year clinical, economic, and environmental burden of CKD in the scenario prescribing SGLT-2i to 75% of eligible patients with CKD (scenario 1), which reflects the broadest eligibility, to each of the less inclusive SGLT-2i eligibility criteria scenarios. Clinical Outcomes Over the 10-year horizon, broader SGLT-2i eligibility criteria were associated with a meaningful decrease in dialysis prevalence, all-cause mortality, and an increase in the prevalence of CKD. Specifically, in scenario 1, where 75% of all eligible patients with CKD received SGLT-2i treatment, the 10-year cumulative number of patients requiring dialysis was projected to be 411,503. Under scenario 2, restricting eligibility to a KDIGO 2024–aligned population increases cumulative dialysis prevalence by 16,520 (+4.0%), to 428,023. Scenario 3 predicted a cumulative dialysis prevalence of 469,255, an increase of 57,752 cases (+14.0%). Scenario 4 predicted a cumulative dialysis prevalence of 482,021, an increase of 70,518 cases (+17.1%). Scenario 5 predicted the highest burden, with a cumulative dialysis prevalence of 482,294, an increase of 70,791 cases (+17.2%) compared with scenario 1 (Figure 1). In addition, scenario 1 was projected to result in 2,984,487 cumulative all-cause mortality events over the 10-year time horizon. Scenario 2 predicted an increase of cumulative mortality by 38,570 (+1.3%), to 3,023,057. When restricting to patients without T2D with UACR < 200 mg/g in scenario 3, mortality was projected to increase by 89,632 (+3.0%), to 3,074,119. Scenario 4 predicted cumulative mortality to reach 3,089,956, an increase of 105,470 (+3.5%). Scenario 5 predicted the highest increase, with mortality projected to increase by 128,270 (+4.3%), to 3,112,757, when comparing with broad SGLT-2i access (Figure 2). Driven by the reduced mortality in scenario 1, where all patients with CKD were prescribed SGLT-2i, prevalence of CKD at the end of the 10-year time horizon, in 2035, was projected to be 9,704,104. In scenario 2, CKD prevalence in 2035 was projected to decrease by 45,328 (−0.5%), to 9,658,776. In scenario 3, CKD prevalence in 2035 was projected to decrease by 96,664 (−1.0%), to 9,607,441. In scenario 4, CKD prevalence in 2035 was projected to decrease by 112,911 (−1.2%) to 9,591,194. Lastly, the greatest decrease was projected to occur in scenario 5, under current usage, by 135,711 (−1.4%), to 9,568,393 (Supplementary Figure S1). Sensitivity analyses exploring varying levels of SGLT-2i uptake (60% and 90%) demonstrated consistent projections with slightly different magnitudes. Decreased SGLT-2i uptake (60%) generally resulted in increased dialysis prevalence and mortality while decreasing CKD prevalence; whereas increased SGLT-2i uptake (90%) generally resulted in decreased dialysis prevalence and mortality while increasing CKD prevalence compared with the 75% uptake scenario (Supplementary Table S2).Figure 1Projected prevalence of dialysis dependence over 10 years. CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio.Figure 2Projected annual all-cause mortality incidence among the CKD population over 10 years. CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio. Projected prevalence of dialysis dependence over 10 years. CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio. Projected annual all-cause mortality incidence among the CKD population over 10 years. CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio. Economic Outcomes Considering that economic outcomes are directly tied to the clinical patient numbers, similar trends were observed. In scenario 1, cumulative non-KRT CKD costs were projected to be £43,934,208,018. In scenario 2, cumulative non-KRT CKD costs were predicted to increase by £292,167,419 (+ 0.7%), to £44,226,375,436. In scenario 3, cumulative non-KRT CKD costs were predicted to increase by £318,309,918 (+ 0.7%), to £44,252,517,936 when restricting patients without T2D with UACR < 200 mg/g. In scenario 4, there was a predicted increase of £462,759,681 (+ 1.1%), to £44,396,967,699. The largest increase was predicted in scenario 5, reaching an increase of £927,113,763 (+ 2.1%), to £44,861,321,780, compared with scenario 1 (Supplementary Figure S2). Similarly, costs related to KRT were projected to be £15,193,608,881, when no SGLT-2i restrictions are in place in scenario 1. In scenario 2, KRT costs were projected to increase by £370,853,727 (+ 2.4%), to £15,564,462,608 when restricting to the KDIGO-recommended population. In scenario 3, the cumulative KRT costs were projected to increase by £1,332,619,206 (+8.8%) to £16,526,228,087, when restricting patients without T2D with UACR < 200 mg/g. In scenario 4, the cumulative KRT costs were projected to increase by £1,599,157,242 (+10.5%), to £16,792,766,123. Scenario 5 was projected to reach £16,803,698,590 in cumulative KRT costs, an increase of £1,610,089,709 (+10.6%), when compared with scenario 1 (Figure 3). In contrast, because more patients are treated with SGLT-2i when no restrictions are in place, total costs (non-KRT CKD, KRT, and incremental SGLT-2i costs) in scenario 1, valued at £93,323,566,956, were projected to decrease by £14,143,797,719 (−15.2%) to £79,179,769,236, in scenario 2, when restricting to the KDIGO-recommended population. In scenario 3, total costs were projected to decrease by £19,139,435,454 (−20.5%) to £74,184,131,501. Scenario 4 projected a further decrease to £71,225,756,389, a reduction of £22,097,810,657 (−23.7%). Scenario 5 projected the largest decrease of £31,658,546,585 (−33.9%) to £61,665,020,370, when compared with broad SGLT-2i access (Supplementary Figure S3).Figure 3Projected KRT-related costs over 10 years. CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney replacement therapy; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio. Includes costs related to both dialysis and transplant. Discounts were applied annually at an aggregate level at a rate of 3.5%. Projected KRT-related costs over 10 years. CKD, chronic kidney disease; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney replacement therapy; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio. Includes costs related to both dialysis and transplant. Discounts were applied annually at an aggregate level at a rate of 3.5%. Environmental Outcomes Considering that SGLT2i usage reduces CKD progression to later disease stages and dialysis dependence, environmental outcomes were projected to improve with broader SGLT-2i eligibility. Overall (CKD and KRT) cumulative freshwater consumption was projected to be 268,864,888 m3 in scenario 1. In scenario 2, this burden was projected to increase by 393,378 m3 (+0.1%) to 269,258,266 m3, when restricting to the KDIGO-recommended population. Scenario 3 was projected to result in an increase of 2,292,774 m3 (+0.9%) to 271,157,662 m3. Scenario 4 was projected to result in an increase of 2,886,986 m3 (+1.1%) to 271,751,874 m3. The largest increase was projected in scenario 5, with an increase of 3,177,313 m3 (+1.2%) to 272,042,201 m3, when compared with the broadest eligibility scenario (Supplementary Figure S4). Overall fossil fuel depletion was projected to reach 25,693,210,110 kg oil equivalents (eq) in scenario 1. An increase of 89,328,098 kg oil eq (+0.3%) to 25,782,538,208 kg oil eq, was projected in scenario 3 when restricting patients without T2D with UACR < 200 mg/g. Scenario 4 was projected to increase to 25,810,967,869 kg oil eq, an increase of 117,757,759 kg oil eq (+0.5%). The largest increase was projected for scenario 5, with an increase of 143,889,681 kg oil eq (+0.6%) to 25,837,099,791 kg oil eq, when compared with scenario 1. A marginal decrease of 1,694,479 kg oil eq (0.0%) to 25,691,515,631 kg oil eq was projected when restricting to the KDIGO-recommended population in scenario 2 (Supplementary Figure S5). Similarly, overall carbon footprint was projected to result in 58,153,927,895 kg CO2 eq in scenario 1, the least restrictive scenario. In scenario 3, this burden was projected to increase by 193,468,722 kg CO2 eq (+0.3%) to 58,347,396,617 kg CO2 eq, when restricting patients without T2D with UACR < 200 mg/g. In scenario 4, cumulative overall carbon footprint was projected to increase by 255,457,013 kg CO2 eq (+0.4%), to 58,409,384,908 kg CO2 eq. The largest increase was projected in scenario 5, with an increase of 308,795,079 kg CO2 eq (+0.5%), to 58,462,722,974 kg CO2 eq, compared with the least restrictive scenario. A marginal decrease of 7,222,800 kg CO2 eq (0.0%), to 58,146,705,095 kg CO2 eq, was projected when restricting to the KDIGO-recommended population in scenario 2 (Supplementary Figure S6). Cumulative freshwater consumption from KRT was projected to reach 21,987,409 m3 in scenario 1, without SGLT-2i restrictions, and increase as scenarios get more restrictive due to more patients progressing to KRT with less SGLT-2i use. Prescription to the KDIGO-recommended population only, in scenario 2, was projected to increase KRT-related freshwater consumption by 760,944 m3 (+3.5%) to 22,748,353 m3. Restriction to patients without T2D with UACR < 200 mg/g in scenario 3 was projected to increase freshwater consumption from KRT by 2,669,876 m3 (+12.1%) to 24,657,284 m3. In scenario 4, freshwater consumption was projected to increase by 3,258,788 m3 (+14.8%), to 25,246,197 m3. In the current usage scenario (scenario 5), further consumption was projected to increase by 3,273,119 m3 (+14.9%) to 25,260,528 m3, representing the largest increase compared with scenario 1 (Supplementary Figure S7). Cumulative fossil fuel depletion from KRT was projected to reach 169,570,077 kg oil eq in scenario 1, when no restrictions are placed on SGLT-2i prescription. Fossil fuel depletion was projected to increase by 36,120,487 kg oil eq (+3.1%) to 1,205,690,564 kg oil eq, when restricting to the KDIGO-recommended population in scenario 2. In scenario 3, an increase of 127,223,139 kg oil eq (+10.9%) to 1,296,793,216 kg oil eq was projected with restrictions to patients without T2D with UACR < 200 mg/g. In scenario 4, an increase of 155,223,480 kg oil eq (+13.3%) to 1,324,793,557 kg oil eq was projected. The largest increase was projected in scenario 5, where the cumulative fossil fuel depletion reaches 1,325,562,223 kg oil eq, an increase of 155,992,146 kg oil eq (+13.3%) when compared with scenario 1 (Supplementary Figure S8). Lastly, KRT-related carbon footprint was projected to reach 2,633,413,175 kg CO2 eq in scenario 1. In scenario 2, carbon was projected to increase by 81,273,554 kg CO2 eq (+3.1%) to 2,714,686,729 kg CO2 eq, when restricted to the KDIGO-recommended population. An increase of 286,250,221 kg CO2 eq (+10.9%) to 2,919,663,395 kg CO2 eq was projected in scenario 3 with non-T2D UACR restrictions. In scenario 4, carbon footprint was projected to increase by 349,251,909 kg CO2 eq (+13.3%), to 2,982,665,083 kg CO2 eq. Lastly, in scenario 5, the carbon footprint was projected to be 2,984,392,739 kg CO2 eq, an increase of 350,979,565 kg CO2 eq (+13.3%) when compared with scenario 1 (Figure 4).Figure 4Projected carbon footprint owing to KRT over 10 years. CKD, chronic kidney disease; eq, equivalent; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney replacement therapy; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio. Projected carbon footprint owing to KRT over 10 years. CKD, chronic kidney disease; eq, equivalent; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney replacement therapy; T2D, type 2 diabetes; UACR, urine albumin creatinine ratio. Discussion Key Findings Using the validated IMPACT CKD model, we projected the clinical, economic, and environmental burdens for CKD, given various levels of SGLT-2i use over a 10-year time horizon to evaluate the impact of broad and restrictive SGLT-2i use. As expected, broader eligibility criteria were projected to generally decrease the holistic burden of CKD compared with more restrictive use scenarios. Specifically, broader use was projected to delay disease progression, keeping patients at earlier, less burdensome stages, and away from dialysis. We have projected substantial mortality benefits. Such gains come at the cost of modestly higher CKD prevalence, because of improved survival, rather than increased disease incidence, as well as increases in overall health care costs, driven by more patients being treated with and incurring the cost of SGLT-2i treatment. In contrast, the costs of CKD (excluding KRT) and KRT were projected to decrease in the more inclusive scenarios. As such, broader access shifts costs upstream to pharmacy costs while avoiding downstream KRT-related burden and mortality. Environmental impacts are similarly favorable because dialysis is the most environmentally damaging aspect of CKD management. The projected environmental benefits due to a reduction in KRT with the broadest access scenario, are equivalent to a decrease in annual water use of approximately 20,000 households, the yearly electricity consumption of approximately 2.08 million lightbulbs, and the annual CO2 emissions from approximately 76,000 passenger vehicles compared with the current usage scenario.19, 20, 21 As expected, the sensitivity analyses demonstrate that decreased SGLT-2i uptake (60%) resulted in a projected decrease in CKD prevalence, with an increase in dialysis prevalence and mortality. The reverse is seen when SGLT-2i uptake is increased (90%). When interpreting results, it is important to note, although the scenario assuming broad CKD access to SGLT-2is produced the most favorable outcomes, it was intentionally designed as a maximally inclusive case to illustrate the full potential range of SGLT-2i benefits. The scenario reflects recent guidance that recommends providing access to SGLT-2is to all adults with CKD, regardless of diabetes status and CKD risk level.11,12 Policy And Sustainability Implications NHS England aims to improve kidney care and management by reducing the dialysis burden, slowing CKD progression, and achieving net-zero health care emissions, which are supported by early intervention, enhancing the quality of life for those affected.1,22,23 In the past year, NHS England recommended SGLT-2i use in the 2024/2025 Quality and Outcomes Framework guidance, and acknowledged existing barriers to access.24,25 Current guidelines are one such barrier for SGLT-2i eligibility.13 Misaligned criteria between the relevant guidelines contribute in part to the underprescription of SGLT-2i despite their effectiveness, with a recent study showing only a fraction (17%) of eligible patients prescribed SGLT-2i as indicated. Patients with CKD without T2D were less likely to obtain a prescription, with only 0.01% of indicated patients prescribed, compared with 22% of patients with CKD and T2D.13 To date, primary care has not implemented key strategies for the expanded use of SGLT-2i such as improved coding accuracy, risk-based care, or financial incentives, which are tools that typically drive success in meeting quality-of-care indicators and improving population-level kidney health.26 Our findings support the benefit of broader SGLT-2i eligibility to encourage early intervention and align with goals from the NHS to manage CKD progression. Drug costs are partially offset by savings in KRT and late-stage CKD management. For context, though the threshold for the willingness-to-pay for therapies varies by health system, an intervention is deemed cost-effective below a threshold of £20,000 to £30,000 increased cost per quality-adjusted life-year according to the Institute for Clinical and Economic Review.27 Although this study is not a cost-effectiveness analysis with an incremental cost-effectiveness ratio output, it is important to recognize that the increased costs from appropriate use of treatment constitute investments resulting in survival benefits for patients suffering from CKD, consistent with value-based prescribing.28 Aligning with trends of the clinical and economic outcomes, both overall and KRT-related environmental outcomes were projected to decrease with broader SGLT-2i eligibility criteria due to shifts to earlier CKD stages with more patients being treated. Dialysis, being the dominant form of KRT, is one of the most environmentally burdensome clinical care services due to its high consumption of energy, water, and single use plastics.29 Therefore, fewer patients progressing to require dialysis will greatly alleviate the environmental burden of CKD. Together, these projections underscore the need to mitigate the barriers to SGLT-2i access as recommended by NHS England to improve clinical, economic, and environmental outcomes with broader SGLT-2i use.1,23 Limitations Key limitations of this study are inherent to microsimulation models and include the need for simplifying assumptions to facilitate the modelling of a complex disease with accompanying comorbidities such as CKD. The analysis assumes that no new CKD guidelines are introduced in the 10-year time horizon; therefore, the projections reflect the best current knowledge. In addition, whereas a 3.5% discount rate was applied annually for economic outcomes, no adjustments were applied to water usage, fossil fuel depletion, and carbon emissions related to CKD, meaning that the results represent current conditions. Therefore, the analysis assumes that environmental effects are based on the continuation of existing care administration practices and does not incorporate potential advancements such as telemedicine. Because of ongoing decarbonization efforts, it is possible that the environmental impact of CKD could shift over time.30 A further limitation relates to the price of SGLT-2i, a key driver of the cost projections, which is likely to change over a 10-year window, and any reduction in price over time may shift cost outcomes in favor of broader accessibility scenarios. In addition, we assumed 75% of all patients eligible for SGLT-2i treatment in each scenario would be treated, which may exceed the real-world adoption and patient adherence. Nonetheless, the sensitivity analyses conducted with alternative SGLT-2i uptake scenarios produced projections that followed consistent trends, with slight differences in magnitude as expected. Although treatment was modelled by CKD stage, the resulting treatment effects were consistent across all stages, potentially overestimating the benefits of SGLT-2i in lower-risk populations. Similarly, though SGLT-2is consistently reduce kidney disease progression, heart failure events, and CV mortality in patients with CKD, their effects on stroke and MI are not consistent across the literature.6,31,32 Although some meta-analyses suggest reductions in the occurrence of nonfatal stroke and MI,6,32 these findings are not uniformly observed, and may not consistently reach statistical significance.31 As a result, uncertainty in the magnitude of benefits on stroke and MI incidence may be seen. In addition, we assumed that 100% of patients with CKD were diagnosed and eligible for risk stratification for the purposes of this analysis, which is an overestimation of diagnosis within the population in the real-world. Furthermore, because comprehensive databases covering all required population inputs are unavailable, the IMPACT CKD model requires large amounts of inputs which are collected from a range of studies varying in populations, time, methodology, and quality. Although the model uses the best available evidence for each parameter, drawing from multiple heterogeneous sources and the absence of formal uncertainty estimation introduce additional uncertainty in the projections. Lastly, uncertainty in the exact proportion of patients currently using SGLT-2i may impact the magnitude of projections. Conclusion In conclusion, the projected results from our study suggest that expanding access to SGLT-2i will likely reduce the holistic burdens of CKD, including reducing dialysis dependence, saving lives, and lessening multiple metrics of environmental harm, as compared with current albuminuria- or diabetes-restricted eligibility. Decisions on broadening access to SGLT-2i should consider the multidimensional impact of limiting treatment to patients with CKD. The projected benefits of broad SGLT-2i use in patients with CKD support the NHS’ priorities in reducing dialysis burden, managing CKD progression, and addressing inequities in access-to-care for CKD populations. Disclosure SP, AZ, and BL are employees of EVERSANA; AstraZeneca contracted EVERSANA to complete this study. NR and CF are employees of AstraZeneca. NT, FA, and SC received honoraria for participating in consultant meetings for AstraZeneca. NT received grants or contracts from CIHR, NIH, KFOC, Bayer, AstraZeneca, Boehringer Ingelheim, Janssen Pharmaceuticals, Research Manitoba, Otsuka Pharmaceutical Co, Ltd, Tricida Inc., and Eli Lilly and Company. NT received consulting fees and/or honoraria from Bayer, Boehringer Ingelheim, Janssen Pharmaceuticals, GSK, Otsuka Pharmaceutical Co, Ltd, ProKidney, Roche, Vera, Tricida Inc., and Eli Lilly and Company. NT received equity from ProKidney and Klinrisk. NT has a patent pending for a microfluidic device for point of care detection of urine albumin. NT has a leadership or fiduciary role in AstraZeneca, Janssen, BI-Lilly, Otsuka, and the National Kidney Foundation. NT is a stockholder of ClinPredict, Klinrisk, Quanta, Marizyme, Mesentech, Renibus Therapeutics, Pulsedata, and Tricida. SC received consulting fees from Alexion for participation in a trial steering committee and honoraria from Boehringer Ingelheim, GSK, Astellas, Novartis, and NovoNordisk.